TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:21
Aligos Therapeutics Inc. ( ALGS ) https://www.aligos.com
43.37USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ALGS
164.05%
SPY
32.66%
-85.75%
ALGS
SPY
108.59%
ALGS
0.00%
SPY
302.52%
ALGS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
249.89
183.90
0.79
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.25
41.67
4.99
-342.31
0.00
-2.14
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1586.37
100.00
-1877.95
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-82.09
-73.57
0.00
Other Earnings and Cash Flow Stats:
Aligos Therapeutics Inc. ( ALGS ) Net Income TTM ($MM) is -76.95
Aligos Therapeutics Inc. ( ALGS ) Operating Income TTM ($MM) is -94.59
Aligos Therapeutics Inc. ( ALGS ) Owners' Earnings Annual ($MM) is 0.00
Aligos Therapeutics Inc. ( ALGS ) Current Price to Owners' Earnings ratio is 0.00
Aligos Therapeutics Inc. ( ALGS ) EBITDA TTM ($MM) is -91.86
Aligos Therapeutics Inc. ( ALGS ) EBITDA Margin is -1877.95%
Capital Allocation:
Aligos Therapeutics Inc. ( ALGS ) has paid 0.00 dividends per share and bought back 37.224684 million shares in the past 12 months
Aligos Therapeutics Inc. ( ALGS ) has reduced its debt by 2.594 million USD in the last 12 months
Capital Structure:
Aligos Therapeutics Inc. ( ALGS ) Interest-bearing Debt ($MM) as of last quarter is 8
Aligos Therapeutics Inc. ( ALGS ) Annual Working Capital Investments ($MM) are -2
Aligos Therapeutics Inc. ( ALGS ) Book Value ($MM) as of last quarter is 50
Aligos Therapeutics Inc. ( ALGS ) Debt/Capital as of last quarter is 17%
Other Balance Sheet Stats:
Aligos Therapeutics Inc. ( ALGS ) has 35 million in cash on hand as of last quarter
Aligos Therapeutics Inc. ( ALGS ) has 20 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aligos Therapeutics Inc. ( ALGS ) has 6 common shares outstanding as of last quarter
Aligos Therapeutics Inc. ( ALGS ) has 0 million USD of preferred stock value
Academic Scores:
Aligos Therapeutics Inc. ( ALGS ) Altman Z-Score is -7.03 as of last quarter
Aligos Therapeutics Inc. ( ALGS ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Aligos Therapeutics Inc. ( ALGS ) largest shareholder is UBS Group AG owning 14 shares at 0.00 ($MM) value
Carole Nuechterlein(an insider) Bought 7933601 shares of Aligos Therapeutics Inc. ( ALGS ) for the amount of $6029536.76 on 2023-10-25
17.80% of Aligos Therapeutics Inc. ( ALGS ) is held by insiders, and 48.86% is held by institutions
Aligos Therapeutics Inc. ( ALGS ) went public on 2020-10-16
Other Aligos Therapeutics Inc. ( ALGS ) financial metrics:
FCF:-85.11
Unlevered Free Cash Flow:-66.61
EPS:-12.28
Operating Margin:-1586.37
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-153.78
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Aligos Therapeutics Inc. ( ALGS ) :
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.